Extend Biosciences

Extend Biosciences is a private, clinical-stage biotech leveraging its proprietary Half-life Extension Platform (HLEP) to create improved peptide and protein therapeutics. The company's core innovation involves conjugating drug candidates to a vitamin D derivative, which binds to serum vitamin D binding protein (DBP), creating a circulating reservoir that extends half-life from hours to days or weeks. Its most advanced candidate, EB-612, is a once-weekly PTH analog for hypoparathyroidism that has completed a Phase 2a study. The platform has potential applications across multiple metabolic and endocrine disorders with high unmet need.

Proprietary Half-life Extension Platform (HLEP) that conjugates therapeutic peptides/proteins to a vitamin D analog, enabling binding to endogenous vitamin D binding protein (DBP) for sustained release and extended half-life.

Extend competes in the half-life extension technology space against established methods (Fc fusion, PEGylation) and other novel platforms. In hypoparathyroidism, it faces competition from Ascendis Pharma's approved once-daily TransCon PTH. In broader peptide markets, it would compete against large pharma companies with extensive GLP-1 and other metabolic disease portfolios.